Status:
UNKNOWN
Registry of Irreversible Electroporation for the Ablation of Prostate Cancer With Use of Nanoknife Device
Lead Sponsor:
Clinical Research Office of the Endourological Society
Conditions:
Prostate Cancer
Eligibility:
MALE
Brief Summary
The aim of this registry is to assess the recurrence of prostate cancer at 1 and 5 years, as well as the change in functional outcomes (e.g. incontinence or erectile function) from baseline. Secondary...
Detailed Description
This is an international prospective observational multi-center study in which data on consecutive patients for 5 years with prostate cancer who undergo IRE are collected. Data from each patient will ...
Eligibility Criteria
Inclusion
- Is diagnosed with histologically confirmed prostate cancer
- Is scheduled for IRE Nanoknife®
- Has signed informed consent form
Exclusion
- No specific exclusion criteria are defined.
Key Trial Info
Start Date :
November 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2025
Estimated Enrollment :
361 Patients enrolled
Trial Details
Trial ID
NCT02255890
Start Date
November 1 2014
End Date
April 1 2025
Last Update
December 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AMC University Hospital
Amsterdam, Netherlands, 1105AZ